N/A
N=2,411
Telmisartan 80mg+Hydrochlorothiazide (HCTZ) 25 mg in Hypertension: an Observational Study
Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT00909038 ↗Enrolled (actual)
2,411
Serious AEs
0.0%
Results posted
Apr 2011
Primary outcome: Primary: Rate of BP Control in Hypertensive Patients — 51.3 Percentage of Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boehringer Ingelheim
- Primary completion
- Nov 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of BP Control in Hypertensive Patients |
51.3 | — |
| SECONDARY Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Overall Study Population |
137.3 | — |
| SECONDARY Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Overall Study Population |
80.1 | — |
| SECONDARY Systolic Blood Pressure (SBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk |
144.3 | — |
| SECONDARY Diastolic Blood Pressure (DBP) After at Least 8 Weeks of Treatment in Population at High Cardiovascular Risk |
82.9 | — |
| SECONDARY Rate of BP Control by Risk Factor According to the Recommendations ESH/ESC 2007 |
51.9; 5.0; 3.8; 3.9; 8.3 | — |
Summary
It is a national, retrospective , observational study in hypertensive patients treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg. The primary objective is to assess the control rate (systolic and diastolic blood pressure). Key secondary objectives are to assess the blood pressure reduction after at least 8 weeks of treatment, describe the population treated with this new fixed dose combination
Eligibility Criteria
Inclusion criteria
- Hypertensives
- Treated for at least 8 weeks with the fixed dose combination of telmisartan 80 mg and hydrochlorothiazide 25 mg
Exclusion criteria
- Treated with the combination less than 8 weeks
Data sourced from ClinicalTrials.gov (NCT00909038). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.